Aytu Biopharma Inc., a pharmaceutical company specializing in novel therapeutics, has announced the pricing of an upsized public offering of common stock, raising approximately $14.4 million. The offering includes 9,600,000 shares at an effective price of $1.50 per share, with an additional option for underwriters to purchase up to 1,440,000 more shares. The proceeds are intended for general corporate purposes and to support the exclusive commercialization of EXXUA™ (gepirone) extended-release tablets for major depressive disorder in the U.S. The offering is expected to close shortly, pending standard conditions, with Lake Street Capital Markets, LLC serving as the sole book runner.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.